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Summary
 
Objective
 
Retinol-binding protein 4 (RBP4) is a recently identiﬁed
adipokine that is elevated in the serum in several insulin-resistant
states. We investigated the relationship between non-alcoholic fatty
liver disease (NAFLD) and serum RBP4 in nondiabetic adults.
 
Methods
 
One hundred and ﬁfty-nine nondiabetic, non-alcoholic
subjects (95 males and 64 females) participated in this study.
Division of subjects into a NAFLD group (
 
n
 
 = 73; 45 males and 28
females) or a normal group (
 
n
 
 = 86; 50 males and 36 females) was
based on the presence of fatty liver disease determined by sonography.
 
Results
 
Serum RBP4 levels in the NAFLD group were signiﬁcantly
higher than those in the normal group (62·8  ±  16·0  mg/l 
 
vs.
 
51·7 ± 14·6 mg/l, 
 
P
 
 < 0·0001). Multiple logistic regression analysis
revealed that the RBP4 level was an independent factor associated
with NAFLD (
 
P = 
 
0·0042). In addition, serum RBP4 levels were
positively correlated with serum alanine aminotransferase (ALT),
aspartate aminotransferase (AST) and 
 
γ
 
-glutamyltranspeptidase
(GGT) levels. The signiﬁcant association between serum RBP4 and
GGT levels remained even after adjusting for age, gender, body mass
index, the homeostasis model of assessment (HOMA) value and the
presence of NAFLD (
 
r
 
 =
 
 
 
0·3097, 
 
P
 
 = 0·0002).
 
Conclusion
 
Serum RBP4 levels are signiﬁcantly associated with
NAFLD and liver enzymes.
(Received 17 May 2007; returned for revision 15 June 2007; ﬁnally 
revised 11 August 2007; accepted 6 September 2007)
 
Introduction
 
Non-alcoholic fatty liver disease (NAFLD) is a major liver disease
found throughout the world. It has a broad spectrum of manifesta-
tions ranging from simple steatosis to non-alcoholic steatohepatitis
and cirrhosis.
 
1,2
 
 Obesity, hyperglycaemia, type 2 diabetes (T2DM) and
hypertriglycaeridaemia are known risk factors for the development
of NAFLD. NAFLD is therefore regarded as a manifestation of the
metabolic (or insulin resistance) syndrome.
 
3–6
 
 Although its clinical
association seems to be well established, the pathogenesis of NAFLD
has not been fully elucidated. As obesity is the most important risk
factor for insulin resistance, adipose tissue and adipokines have
become the focus of study for NAFLD. Adiponectin is a representative
adipokine that is associated with NAFLD. We have previously reported
that serum adiponectin levels are signiﬁcantly reduced in NAFLD
subjects compared to healthy controls.
 
7
 
 Moreover, recombinant
adiponectin improves insulin resistance and fatty liver disease by
neutralizing tumour necrosis factor-
 
α
 
 (TNF-
 
α
 
) activity in mice.
 
8
 
Retinol-binding protein 4 (RBP4) is a newly identiﬁed adipokine
that is elevated in the serum in several insulin-resistant states.
 
9
 
 Yang
 
et al.
 
 have reported that elevation of serum RBP4 causes systemic
insulin resistance, and reduction of serum RBP4 improves insulin
action in mice.
 
9
 
 Likewise, serum RBP4 levels correlated with the
magnitude of insulin resistance in human subjects with obesity,
impaired glucose tolerance or T2DM.
 
10
 
 Furthermore, RBP4
levels have been shown to decrease in subjects in whom insulin
resistance improved after exercise training.
 
10
 
 The close relationship
between NAFLD and insulin resistance or obesity suggests that
this new adipokine may play a role in the pathogenesis of NAFLD.
Therefore, this study was designed to investigate whether there is a
relationship between NAFLD and serum RBP4 levels in nondiabetic
adults.
 
Methods
 
Subjects and measurement
 
The participants in this study were recruited from individuals who
were self-referred for a routine health check-up at Korea University
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Ansan Hospital. The medical health check-up provided by the
hospital included an abdominal ultrasound. We enrolled patients
found to have a fatty liver. Thereafter, we selected subjects who did not
have a fatty liver, matched for age and gender, as controls. Subjects
were excluded from this study if they met any of the following
criteria: (i) alcohol drinking >140 g/week; (ii) a positive test for
hepatitis B surface antigen or hepatitis C antibody; (iii) evidence
of toxic hepatitis; (iv) presence of previously diagnosed diabetes
or fasting glucose 
 
≥
 
 7·0 mmol/l; (v) other endocrine disease (e.g.
thyroid dysfunction); (vi) known liver or renal dysfunction; or
(vii) age < 20 or > 80 years. All subjects denied taking drugs known
to promote fatty liver disease or to cause insulin resistance over the
past 3 months. As a result of the baseline investigations including the
abdominal ultrasound, 73 subjects (45 males and 28 females) with
fatty liver and 86 healthy subjects (50 males and 36 females) matched
for age and gender as normal controls were enrolled in this study.
Informed consent was obtained from all subjects before enrolment
in the study, which was approved by the ethics committee of the
institution. Clinical data such as age, gender, height, weight and body
mass index were recorded. Systolic and diastolic pressures were
measured by a baumanometer (W.A. Baum, New York, NY) on the
arm of a seated subject who had rested in a sitting position for 10 min
before the measurement. Body fat mass and body fat percentage were
measured by bioelectrical impedance analysis (Inbody 3·0; Biospace,
Seoul, Korea). Waist-to-hip ratio (cm/cm) was determined by
measurement of the circumference of waist and hip in the standing
position. Waist circumference was measured to the nearest 0·1 cm
at the level of the iliac crest by a tape while the subject was at minimal
respiration. Hip circumference was measured at the level of the anterior
superior iliac spine. Blood samples were drawn after an overnight
fast and immediately centrifuged. Serum total cholesterol, trigly-
cerides,  high-density lipoprotein (HDL) cholesterol, low-density
lipoprotein (LDL) cholesterol, uric acid and liver enzyme levels were
determined by enzymatic methods with a chemistry analyser (TBA
200-FR, Toshiba, Japan). Plasma glucose was measured by the glucose
oxidase method. High-sensitivity C-reactive protein (hsCRP) was
determined by nephelometry (IMMAGE, Beckman Coulter, Fullerton,
CA). Serum insulin was measured with an insulin radioimmunoassay
kit (Biosource, Nivelles, Belgium), which had a reactivity of less than
0·2% to human proinsulin. Insulin resistance was estimated using the
homeostasis model of assessment (HOMA), calculated as fasting glucose
(mmol/l) 
 
×
 
 fasting insulin (mU/l)/22·5.
 
11
 
 Serum RBP4 concentrations
were determined with an enzyme-linked immunosorbent assay using
a commercial kit (AdipoGen, Seoul, Korea). The analysis used a RBP4
competitive  ELISA system where 100 
 
µ
 
g/l of recombinant human
RBP4 expressed by an animal cell line (HEK293 cells) was coated onto
a plate and varying concentrations of the recombinant RBP4 and
a polyclonal antibody were added to the plate for a competitive
reaction resulting in a standard curve. We performed a quantitative
Western-equivalent analysis using a phosphoimage analyser
(Fusiﬁlm Co. LAS-1000, Tokyo, Japan) with the recombinant RBP4;
its intra- and interassay coefﬁcients of variation were 5·5% and
7·2%, respectively. We evaluated several serum samples during
this study (
 
n
 
 = 14) using Western blot analysis of RBP4. The RBP4
concentrations by Western blotting correlated with the results of
the AdipoGen ELISA kits (
 
r
 
 =
 
 
 
0·812, 
 
P
 
 < 0·001, 
 
n
 
 = 14).
A fatty liver was diagnosed on ultrasonography by a single
experienced radiologist who was blinded to the laboratory data. Of the
four known criteria used for the diagnosis of fatty liver (hepatorenal
echo contrast, liver brightness, deep attenuation and vascular
blurring), the participants were required to have hepatorenal echo
contrast and liver brightness for the diagnosis of fatty liver.
 
12
 
 Subjects
were categorized as the NAFLD group or the normal group based
on the detection of a fatty liver by sonography.
 
Statistical analyses
 
Data for anthropometric and metabolic characteristics of the study
subjects were expressed as means ± SD or 
 
n
 
 (%). Variables that were
skewed to the right were log-transformed for subsequent analysis.
Differences between mean values of the NAFLD and normal groups
were examined using the Student’s 
 
t
 
-test or 
 
χ
 
2
 
 test. The association
of RBP4 with NAFLD was investigated using the multiple logistic
regression analysis that was adjusted for age, gender, body mass
index, waist circumference, body fat per cent, systolic and diastolic
pressure, fasting glucose, HOMA, total cholesterol, triglycerides and
HDL cholesterol. Pearson’s correlation analysis was performed
to  establish the relationship between RBP4 and anthropometric,
metabolic parameters and various liver enzymes in all subjects and
then evaluated by gender. Statistical signiﬁcance was accepted for
 
P
 
-values of < 0·05. All statistical analyses were performed using 
 

 
version 9·13 (SAS Institute, Cary, NC). 
 
Results
 
Serum RBP4 levels in NAFLD
 
The characteristics of the study subjects are summarized in Table 1.
The distribution of age and gender between the normal and the
NAFLD groups was not different. Male participants comprised
58·1% of the normal group and 61·6% of the NAFLD group. The
subjects in the NAFLD group had a greater weight, body mass
index, waist circumference, waist-to-hip ratio, body fat mass, body fat
per cent, systolic blood pressure, diastolic blood pressure, total
cholesterol, triglycerides, LDL cholesterol, fasting glucose, fasting
insulin,  HOMA, HbA1c, uric acid, alanine aminotransferase
(ALT), aspartate aminotransferase (AST), alkaline phosphatase
(ALP), 
 
γ
 
-glutamyltranspeptidase (GGT), hsCRP and RBP4 levels
than control subjects. However, the HDL cholesterol was signiﬁcantly
lower in the NAFLD group. In all subjects, the mean serum RBP4
levels were 51·7 ± 14·6 mg/l in the normal group and 62·8 ± 16·0 mg/l in
the NAFLD group (
 
P < 
 
0·0001). Male participants had higher levels
of serum RBP4 than females (61·8  ±  14·7  mg/l 
 
vs.
 
  49·3 ± 15·5 mg/l,
 
P
 
 < 0·0001). For both genders, serum RBP4 levels in the NAFLD
group were signiﬁcantly higher than in the normal group (Table 1).
Multiple logistic regression analysis was performed using NAFLD
as a dependent variable. RBP4 was selected as a signiﬁcant variable
together with the body mass index, HOMA and HDL cholesterol
level in all subjects (Table 2). We also performed multiple logistic
regression analysis within each gender. In males, the RBP4 level
{
 
P = 
 
0·0539; odds ratio (OR) [95% conﬁdence interval (CI)]: 1·058
(0·999–1·120)} was a marginally signiﬁcant variable together with 
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Table 1. Anthropometric and metabolic characteristics of the study subjects
Variable
Total Male§ Female§
Normal 
(n = 86)
NAFLD 
(n = 73) P-value†
Normal 
(n = 50)
NAFLD 
(n = 45)
Normal 
(n = 36)
NAFLD 
(n = 28)
Age (years) 49·7 ± 10·1 49·6 ± 12·5 0·9493 48·8 ± 10·9 47·3 ± 10·6 51 ± 8·9 53·4 ± 14·4
Gender, male (%) 50 (58·1) 45 (61·6) 0·6534
Weight (kg) 63·9 ± 9·8 72·6 ± 9·2 < 0·0001 68·8 ± 8·7 77 ± 7·0*** 57·2 ± 7·0 65·6 ± 8·1***
Body mass index (kg/m
2) 23·7 ± 2·4 27 ± 2·3 < 0·0001 24 ± 2·2 26·6 ± 1·8*** 23·2 ± 2·7 27·7 ± 2·8***
Waist circumference (cm) 80·2 ± 7·3 88·6 ± 5·8 < 0·0001 82·9 ± 6·1 89·1 ± 5·1*** 76·4 ± 7·1 87·9 ± 6·9***
Waist-to-hip ratio (cm/cm) 0·86 ± 0·05 0·92 ± 0·06 < 0·0001 0·89 ± 0·04 0·92 ± 0·04*** 0·83 ± 0·05 0·92 ± 0·08***
Body fat mass (kg) 14·8 ± 4·5 20·5 ± 5·0 < 0·0001 13·8 ± 3·8 18·3 ± 3·6*** 16·3 ± 5·0 23·9 ± 5·2***
Body fat per cent (%) 23·2 ± 6·5 28·4 ± 7·4 < 0·0001 19·8 ± 4·4 23·7 ± 3·7*** 27·8 ± 6·2 35·9 ± 5·3***
Systolic blood pressure (mmHg)‡ 103 ± 1·1 109·7 ± 1·1 0·0027 103·9 ± 1·1 108·7 ± 1·1 101·8 ± 1·1 111·3 ± 1·2*
Diastolic blood pressure (mmHg) 66·1 ± 10·1 69·8 ± 10·4 0·0241 66·8 ± 10·0 68·9 ± 8·6 65·1 ± 10·3 71·3 ± 12·8*
Total cholesterol (mmol/l) 5·0 ± 0·8 5·4 ± 0·9 0·0045 5·0 ± 0·8 5·5 ± 0·7** 5·0 ± 0·9 5·4 ± 1·2
Triglyceride (mmol/l)‡ 1·5 ± 1·7 2·2 ± 1·7 < 0·0001 1·8 ± 1·6 2·3 ± 1·6* 1·1 ± 1·6 2·0 ± 1·8***
HDL cholesterol (mmol/l)‡ 1·2 ± 1·3 1·1 ± 1·2 < 0·0001 1·1 ± 1·2 1·0 ± 1·2*** 1·4 ± 1·3 1·2 ± 1·2***
LDL cholesterol (mmol/l) 2·9 ± 0·6 3·2 ± 0·8 0·0150 2·9 ± 0·6 3·2 ± 0·6* 2·8 ± 0·7 3·0 ± 1·0
Fasting glucose (mmol/l) 5·1 ± 0·6 5·4 ± 0·6 0·0002 5·1 ± 0·4 5·4 ± 0·5** 5·1 ± 0·7 5·5 ± 0·6*
Fasting insulin (pmol/l) 54·8 ± 16·9 79·2 ± 27·1 < 0·0001 57·1 ± 19·4 76 ± 22·5*** 51·6 ± 12·3 84·3 ± 32·8***
HOMA‡ 1·6 ± 1·4 2·5 ± 1·5 < 0·0001 1·7 ± 1·4 2·4 ± 1·4*** 1·5 ± 1·3 2·6 ± 1·6***
HbA1c (%) 5·6 ± 0·5 5·8 ± 0·4 0·0066 5·5 ± 0·4 5·7 ± 0·4** 5·7 ± 0·6 5·9 ± 0·4
Uric acid (µmol/l) 309 ± 89 363 ± 83 0·0005 363 ± 71 399 ± 77* 24·4 ± 59 303 ± 59***
ALT (IU/l)‡ 15·4 ± 1·5 30·9 ± 1·7 < 0·0001 17·4 ± 1·4 36·6 ± 1·6*** 13 ± 1·4 23·6 ± 1·6***
AST (IU/l)‡ 19·4 ± 1·2 25·8 ± 1·4 < 0·0001 19·8 ± 1·2 27·7 ± 1·4*** 18·9 ± 1·2 22·9 ± 1·4*
ALP (IU/l)‡ 62·1 ± 1·3 71·2 ± 1·3 0·0019 65·5 ± 1·3 66·7 ± 1·3 57·8 ± 1·3 79 ± 1·4***
GGT(IU/l)‡ 21·6 ± 1·7 41 ± 1·9 < 0·0001 28·4 ± 1·7 50·7 ± 1·9*** 14·7 ± 1·4 29·1 ± 1·7***
hsCRP (mg/l)‡ 0·06 ± 2·82 0·12 ± 2·54 < 0·0001 0·06 ± 2·63 0·09 ± 2·41* 0·05 ± 3·08 0·17 ± 2·42***
RBP4 (mg/l) 51·7 ± 14·6 62·8 ± 16·0 < 0·0001 58·7 ± 13·1 65·3 ± 15·8* 41·8 ± 10·4 58·9 ± 15·9***
†P-values are for differences between the NAFLD group and the control group using Student’s t-test or the χ
2 test (for gender) with total subjects.
‡Geometric means and standard deviations are given. Logarithmic transformed values are used for comparing two groups.
§Within each gender, statistical signiﬁcance by Student’s t-test was indicated by *P < 0·05; **P < 0·01; ***P < 0·001.
Table 2. Multiple logistic regression analysis using NAFLD as a dependent variable with all subjects
Independent variables
NAFLD
Coefﬁcient SE P value OR
 (95% CI)
RBP4 0·0634 0·0222 0·0042 1·065 (1·020–1·113)
Age 0·0094 0·0330 0·7753 1·009 (0·946–1·077)
Gender* 1·5279 1·2262 0·2127 4·608 (0·417–50·96)
Body mass index 0·6519 0·2941 0·0266 1·919 (1·078–3·416)
Waist circumference −0·0964 0·0828 0·2444 0·908 (0·772–1·068)
Body fat per cent 0·0432 0·0944 0·6473 1·044 (0·868–1·256)
Systolic blood pressure 0·0223 0·0388 0·5648 1·023 (0·948–1·103)
Diastolic blood pressure −0·0362 0·0505 0·4725 0·964 (0·874–1·065)
Fasting glucose −0·1860 0·6723 0·7820 0·830 (0·222–3·101)
HOMA 1·3235 0·4668 0·0046 3·757 (1·505–9·378)
Total cholesterol 0·5073 0·3921 0·1957 1·661 (0·770–3·581)
Triglycerides 0·2080 0·2658 0·4340 1·231 (0·731–2·073)
HDL cholesterol −5·9610 1·7103 0·0005 0·003 (< 0·001–0·074)
SE, standard error; OR, odds ratio; CI, conﬁdence interval.
*Reference group = male. 
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total cholesterol [
 
P = 
 
0·0477, OR (95% CI): 1·542 (1·004–2·367)]
and HDL cholesterol levels [
 
P = 
 
0·0031, OR (95% CI): 0·012
(< 0·001–0·226)]. By contrast, the RBP4 level was not signiﬁcantly
associated with NAFLD in females [
 
P = 
 
0·0873, OR (95% CI): 1·130
(0·982–1·299)].
 
Correlations between RBP4, metabolic parameters and 
liver enzymes
 
In all subjects (
 
n
 
 = 159), RBP4 was found to be positively correlated
with body mass index, waist circumference, waist-to-hip ratio, systo-
lic and diastolic blood pressure, total cholesterol, triglycerides, LDL-
cholesterol, fasting glucose, HOMA and uric acid levels, but not with
body fat (Table 3). After adjusting for age, body mass index and the
HOMA value, RBP4 still correlated with waist circumference, waist-
to-hip ratio, diastolic pressure, triglycerides, fasting glucose and uric
acid levels. The signiﬁcant positive correlations between serum RBP4
and diastolic pressure, triglycerides and fasting glucose levels
(
 
r
 
 =
 
 
 
0·1726, 
 
P
 
 = 0·0415; 
 
r
 
 = 0·2304, 
 
P
 
 = 0·0062; 
 
r
 
 = 0·2706, 
 
P
 
 = 0·0012,
respectively) were observed even after adjusting for age, gender, body
mass index, HOMA and the presence of NAFLD. We also performed
correlation analyses within each gender (Table 3). In males, diastolic
blood pressure (
 
P = 
 
0·0136), fasting glucose (
 
P = 
 
0·0018) and HbA1c
levels (
 
P = 
 
0·0062) were found to be positively associated with RBP4
after adjusting for age, body mass index and HOMA. In females, only
triglyceride levels showed a signiﬁcantly positive correlation
(
 
P = 
 
0·0008) with RBP4 levels after adjusting for age, body mass
index and HOMA.
Interestingly, serum RBP4 levels were positively correlated with
serum ALT, AST and GGT levels (Table 3). After adjusting for age,
gender, body mass index and HOMA, serum ALT and GGT levels
were  positively associated with serum RBP4 levels (
 
r
 
 =
 
 
 
0·2009,
 
P
 
 = 0·0169; 
 
r
 
 = 0·3576, 
 
P
 
 < 0·0001,  respectively,  Fig. 1).  Moreover,
the signiﬁcant correlations between serum RBP4 and GGT levels
were maintained even after adjusting for age, gender, body mass
index, HOMA and the presence of NAFLD (
 
r
 
 =
 
 
 
0·3097, 
 
P
 
 = 0·0002).
When we performed the correlation analysis adjusted for age, gender,
HOMA and waist circumference as a marker of abdominal obesity,
there were signiﬁcant correlations between the serum RBP4 levels
and the serum ALT and GGT levels (
 
r
 
 =
 
 
 
0·2004, 
 
P
 
 = 0·0172;
 
r
 
 = 0·3588, 
 
P
 
 < 0·0001, respectively).
 
Discussion
 
RBP4, a recently identiﬁed adipokine, may contribute to systemic
insulin resistance.
 
9
 
 It is well known that NAFLD is associated with
insulin resistance. The present study demonstrated that serum RBP4
concentrations are elevated in nondiabetic subjects with NAFLD
compared to normal healthy controls, and that circulating RBP4 was
an independent factor associated with NAFLD. In addition, there
Table 3. Simple correlation analyses between 
RBP4 levels and various parameters in all subjects 
and for each gender
Parameters (vs. RBP4)
Simple correlation
All (n = 159) Male (n = 95) Female (n = 64)
rPrP rP
Age 0·1096 0·1705 0·1347 0·1955 0·2668 0·0331
Body mass index 0·2174 0·0061 0·1103 0·2900 0·3554 0·0040
Waist circumference 0·3657 < 0·0001 0·2104 0·0418 0·3841 0·0017
Waist-to-hip ratio 0·3814 < 0·0001 0·2130 0·0393 0·4032 0·0010
Body fat mass 0·0796 0·3200 0·1155 0·2676 0·3548 0·0040
Body fat per cent −0·0719 0·3695 0·1212 0·2445 0·3638 0·0031
Systolic blood pressure* 0·2398 0·0024 0·2589 0·0117 0·2523 0·0443
Diastolic blood pressure 0·2404 0·0024 0·2784 0·0066 0·2420 0·0540
Total cholesterol 0·2194 0·0056 0·0984 0·3456 0·3630 0·0032
Triglycerides* 0·4235 < 0·0001 0·1698 0·1017 0·5507 < 0·0001
HDL-cholesterol* −0·1306 0·1019 0·1477 0·1555 −0·0844 0·5076
LDL-cholesterol 0·1769 0·0262 0·0311 0·7658 0·2638 0·0352
Fasting glucose 0·2557 0·0012 0·2539 0·0135 0·3117 0·0122
Fasting insulin 0·1182 0·1511 −0·0607 0·5741 0·3344 0·0084
HOMA* 0·1930 0·0184 0·0266 0·8061 0·3804 0·0025
HbA1c 0·1558 0·0521 0·2348 0·0235 0·2742 0·0297
Uric acid 0·4089 < 0·0001 0·1690 0·1035 0·3786 0·0020
ALT* 0·3599 < 0·0001 0·1803 0·0854 0·4062 0·0009
AST* 0·2428 0·0021 0·0995 0·3399 0·3313 0·0075
ALP* 0·0602 0·4526 −0·1253 0·2289 0·2496 0·0467
GGT* 0·4961 < 0·0001 0·3399 0·0008 0·4851 < 0·0001
hsCRP* 0·0194 0·8090 −0·1117 0·2837 0·2165 0·0857
*Logarithmic transformed values are used. 
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were positive correlations between RBP4 and liver enzymes. Serum
RBP4 levels correlated with several parameters related to insulin
resistance including waist circumference, HOMA index, fasting
glucose and triglycerides levels. Unfortunately, we could not assess
the causal relationship between NAFLD and RBP4 levels because the
present study was designed as a cross-sectional study.
Several previous reports including a study of Korean subjects
 
13
 
have shown that circulating RBP4 levels correlate with body mass
index,
 
10,14
 
 waist circumference
 
13
 
 and insulin resistance.
 
10,13
 
 Similarly,
we found that serum RBP4 levels positively correlated with the insulin
resistance index. The subjects with NAFLD were more obese and more
insulin resistant in our study. Accordingly, obesity and increased
insulin resistance, in subjects with NAFLD, may contribute to
elevation of the circulating RBP4 levels. However, logistic regression
analysis revealed that the RBP4 level was an independent factor
associated with NAFLD. In addition, the results of the correlation
analysis showed that the serum RBP4 level positively correlated with
ALT and GGT levels even after adjusting for age, gender, body mass
index and HOMA. The positive correlations between serum RBP4
and GGT levels were even more prominent in subjects with NAFLD
than in controls after adjusting for age, gender, body mass index
and HOMA (NAFLD subjects: 
 
r
 
 = 0·3478, 
 
P
 
 = 0·0049 
 
vs.
 
 controls:
 
r
 
 = 0·2048, 
 
P = 0·0821). These results suggest that a high RBP4 level
likely indicates a predictor for NAFLD.
It is not yet known whether RBP4 affects lipid metabolism in
hepatocytes. A possible explanation is that RBP4 may inﬂuence the
transactivation of retinoic acid-sensitive transcription factors such
as retinoic acid receptor (RAR) and retinoic acid-X receptor (RXR)
in NAFLD. RXRs bind to DNA as obligate heterodimers with
peroxisome-proliferator activated receptors (PPARs) that regulate
the transcription of genes involved in fatty acid metabolism.
15 Another
possible mechanism explaining the link between RBP4 and NAFLD is
that changes in retinoid metabolism induced by RBP4 might alter the
tissue level of retinol. A previous study reported that normalization
of circulating RBP4 by synthetic retinoid improves insulin resistance.
9
In rodents, it has been reported that RBP4, normally expressed in
liver and hepatocytes, is the principal source of circulating RBP4 under
normal conditions and adipose tissue is the organ expressing the second
highest level of RBP4·
16 Recently, Janke et al. found no signiﬁcant
relationship between adipose tissue RBP4 expression and serum
RBP4 levels in postmenopausal women,
17 and Stefan et al. showed that
circulating RBP4 was not associated with the amount of visceral and
subcutaneous abdominal fat.
18 The above ﬁndings suggest that
adipose tissue is likely to be a less important source of circulating RBP4
in humans than in animals. At present, it is unclear whether the liver
is the major source of circulating RBP4 in humans and which organ
is more responsible for the increase of circulating RBP4 in NAFLD.
In the multiple logistic regression analysis, the association between
NAFLD and RBP4 was observed in all subjects. However, when we
analysed within each gender, the RBP4 level was not a signiﬁcant
factor associated with NAFLD in females, and was a marginally
signiﬁcant variable in males. Serum RBP4 levels were higher in male
subjects than in females, which is consistent with another Korean
study.
13 Our study subjects included pre- and postmenopausal
women (24 pre- and 40 postmenopausal women). Both pre- and
postmenopausal women had signiﬁcantly lower serum RBP4 levels
than men (data not shown). Further study is needed to elucidate
whether this gender difference is due to the small sample size, especially
for females, or if the relationship between the RBP4 level and NAFLD
is actually gender speciﬁc.
Limitations of this study include the following. First, we deﬁned
NAFLD as a fatty liver based on ultrasonography without histological
conﬁrmation. However, we consider ultrasonography to be a
reasonable alternative to liver biopsy in relatively healthy subjects.
According to a recent review, ultrasound scanning, when positive,
can provide a high degree of diagnostic certainty, depending on the
prevalence of fatty liver in the population being studied.
19 A recent
study reported that circulating RBP4 was positively associated with
liver fat content quantiﬁed by magnetic resonance (MR) spectros-
copy. This result is consistent with the ﬁndings of our study.
18 The
second limitation is, as mentioned earlier, that the causal relationship
between NAFLD and the RBP4 level could not be determined because
of the cross-sectional nature of the present study. In conclusion, serum
RBP4 levels are signiﬁcantly associated with NAFLD and various liver
enzymes. These ﬁndings suggest that this newly deﬁned adipokine
might be related to pathogenesis of NAFLD.
Fig. 1 Serum RBP4 levels were positively correlated with log-transformed ALT and GGT after controlling for age, gender, body mass index and HOMA 
(*P = 0·0169, **P < 0·0001 in all subjects).560 J. A. Seo et al.
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